Characteristics of Study Population: Patients Living in Denmark on March 1, 2020, With an IBD Diagnosis Between March 1, 2010, and March 1, 2020
| . | Patients With IBD (N = 60 242)a . | Patients With CD (n=21 547) . | Patients With UC (n=38 589) . |
|---|---|---|---|
| Age by January 1, 2020, y | 50 (36-64) | 46 (32-60) | 53 (39-66) |
| Patient’s age category | |||
| ≤19 y | 1748 (2.9) | 976 (4.5) | 765 (2.0) |
| 20-39 y | 16 296 (27.1) | 7107 (33.0) | 9156 (23.7) |
| 40-59 y | 22 531 (37.4) | 7934 (36.8) | 14 557 (37.7) |
| 60-79 y | 16 387 (27.2) | 4709 (21.9) | 11 655 (30.2) |
| ≥80 y | 3280 (5.4) | 821 (3.8) | 2456 (6.4) |
| Sex | |||
| Female | 32 740 (54.3) | 12 217 (56.7) | 20 466 (53.0) |
| Male | 27 502 (45.7) | 9330 (43.3) | 18 123 (47.0) |
| Charlson comorbidity index | |||
| 0 | 42 539 (70.6) | 15 349 (71.2) | 27 113 (70.3) |
| 1-2 | 13 441 (22.3) | 4737 (22.0) | 8682 (22.5) |
| 3+ | 4262 (7.1) | 1461 (6.8) | 2794 (7.2) |
| Type of IBD | |||
| CD | 21 547 (35.8) | — | — |
| UC | 38 589 (64.1) | — | — |
| Both diagnosis | 106 (0.2) | — | — |
| Medication exposure during March 1, 2020, to February 28, 2021b | |||
| 5-ASA | 16 625 (27.6) | 964 (4.5) | 15 635 (40.5) |
| Thiopurines | 3510 (5.8) | 1900 (8.8) | 1601 (4.1) |
| Methotrexate | 592 (1.0) | 293 (1.4) | 299 (0.8) |
| Systemic corticosteroids | 4748 (7.9) | 1627 (7.6) | 3106 (8.0) |
| Anti-TNF-α agents | 5299 (8.8) | 3427 (15.9) | 1859 (4.8) |
| Anti-interleukin therapeutic agents | 57 (0.1) | 19 (0.1) | 38 (0.1) |
| Selective immunosuppressive agents | 420 (0.7) | 328 (1.5) | 90 (0.2) |
| Ciclosporin/tacrolimus | 38 (0.1) | 11 (0.1) | 26 (0.1) |
| . | Patients With IBD (N = 60 242)a . | Patients With CD (n=21 547) . | Patients With UC (n=38 589) . |
|---|---|---|---|
| Age by January 1, 2020, y | 50 (36-64) | 46 (32-60) | 53 (39-66) |
| Patient’s age category | |||
| ≤19 y | 1748 (2.9) | 976 (4.5) | 765 (2.0) |
| 20-39 y | 16 296 (27.1) | 7107 (33.0) | 9156 (23.7) |
| 40-59 y | 22 531 (37.4) | 7934 (36.8) | 14 557 (37.7) |
| 60-79 y | 16 387 (27.2) | 4709 (21.9) | 11 655 (30.2) |
| ≥80 y | 3280 (5.4) | 821 (3.8) | 2456 (6.4) |
| Sex | |||
| Female | 32 740 (54.3) | 12 217 (56.7) | 20 466 (53.0) |
| Male | 27 502 (45.7) | 9330 (43.3) | 18 123 (47.0) |
| Charlson comorbidity index | |||
| 0 | 42 539 (70.6) | 15 349 (71.2) | 27 113 (70.3) |
| 1-2 | 13 441 (22.3) | 4737 (22.0) | 8682 (22.5) |
| 3+ | 4262 (7.1) | 1461 (6.8) | 2794 (7.2) |
| Type of IBD | |||
| CD | 21 547 (35.8) | — | — |
| UC | 38 589 (64.1) | — | — |
| Both diagnosis | 106 (0.2) | — | — |
| Medication exposure during March 1, 2020, to February 28, 2021b | |||
| 5-ASA | 16 625 (27.6) | 964 (4.5) | 15 635 (40.5) |
| Thiopurines | 3510 (5.8) | 1900 (8.8) | 1601 (4.1) |
| Methotrexate | 592 (1.0) | 293 (1.4) | 299 (0.8) |
| Systemic corticosteroids | 4748 (7.9) | 1627 (7.6) | 3106 (8.0) |
| Anti-TNF-α agents | 5299 (8.8) | 3427 (15.9) | 1859 (4.8) |
| Anti-interleukin therapeutic agents | 57 (0.1) | 19 (0.1) | 38 (0.1) |
| Selective immunosuppressive agents | 420 (0.7) | 328 (1.5) | 90 (0.2) |
| Ciclosporin/tacrolimus | 38 (0.1) | 11 (0.1) | 26 (0.1) |
Values are median (interquartile range) or n (%).
Abbreviations: 5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; IBD, inflammatory bowel disease; TNF-α, tumor necrosis factor α; UC, ulcerative colitis.
A total of 106 were registered with diagnoses of both UC and CD.
Time-varying exposures. Patients can have used medication in more than 1 of these categories in the exposure window.
Characteristics of Study Population: Patients Living in Denmark on March 1, 2020, With an IBD Diagnosis Between March 1, 2010, and March 1, 2020
| . | Patients With IBD (N = 60 242)a . | Patients With CD (n=21 547) . | Patients With UC (n=38 589) . |
|---|---|---|---|
| Age by January 1, 2020, y | 50 (36-64) | 46 (32-60) | 53 (39-66) |
| Patient’s age category | |||
| ≤19 y | 1748 (2.9) | 976 (4.5) | 765 (2.0) |
| 20-39 y | 16 296 (27.1) | 7107 (33.0) | 9156 (23.7) |
| 40-59 y | 22 531 (37.4) | 7934 (36.8) | 14 557 (37.7) |
| 60-79 y | 16 387 (27.2) | 4709 (21.9) | 11 655 (30.2) |
| ≥80 y | 3280 (5.4) | 821 (3.8) | 2456 (6.4) |
| Sex | |||
| Female | 32 740 (54.3) | 12 217 (56.7) | 20 466 (53.0) |
| Male | 27 502 (45.7) | 9330 (43.3) | 18 123 (47.0) |
| Charlson comorbidity index | |||
| 0 | 42 539 (70.6) | 15 349 (71.2) | 27 113 (70.3) |
| 1-2 | 13 441 (22.3) | 4737 (22.0) | 8682 (22.5) |
| 3+ | 4262 (7.1) | 1461 (6.8) | 2794 (7.2) |
| Type of IBD | |||
| CD | 21 547 (35.8) | — | — |
| UC | 38 589 (64.1) | — | — |
| Both diagnosis | 106 (0.2) | — | — |
| Medication exposure during March 1, 2020, to February 28, 2021b | |||
| 5-ASA | 16 625 (27.6) | 964 (4.5) | 15 635 (40.5) |
| Thiopurines | 3510 (5.8) | 1900 (8.8) | 1601 (4.1) |
| Methotrexate | 592 (1.0) | 293 (1.4) | 299 (0.8) |
| Systemic corticosteroids | 4748 (7.9) | 1627 (7.6) | 3106 (8.0) |
| Anti-TNF-α agents | 5299 (8.8) | 3427 (15.9) | 1859 (4.8) |
| Anti-interleukin therapeutic agents | 57 (0.1) | 19 (0.1) | 38 (0.1) |
| Selective immunosuppressive agents | 420 (0.7) | 328 (1.5) | 90 (0.2) |
| Ciclosporin/tacrolimus | 38 (0.1) | 11 (0.1) | 26 (0.1) |
| . | Patients With IBD (N = 60 242)a . | Patients With CD (n=21 547) . | Patients With UC (n=38 589) . |
|---|---|---|---|
| Age by January 1, 2020, y | 50 (36-64) | 46 (32-60) | 53 (39-66) |
| Patient’s age category | |||
| ≤19 y | 1748 (2.9) | 976 (4.5) | 765 (2.0) |
| 20-39 y | 16 296 (27.1) | 7107 (33.0) | 9156 (23.7) |
| 40-59 y | 22 531 (37.4) | 7934 (36.8) | 14 557 (37.7) |
| 60-79 y | 16 387 (27.2) | 4709 (21.9) | 11 655 (30.2) |
| ≥80 y | 3280 (5.4) | 821 (3.8) | 2456 (6.4) |
| Sex | |||
| Female | 32 740 (54.3) | 12 217 (56.7) | 20 466 (53.0) |
| Male | 27 502 (45.7) | 9330 (43.3) | 18 123 (47.0) |
| Charlson comorbidity index | |||
| 0 | 42 539 (70.6) | 15 349 (71.2) | 27 113 (70.3) |
| 1-2 | 13 441 (22.3) | 4737 (22.0) | 8682 (22.5) |
| 3+ | 4262 (7.1) | 1461 (6.8) | 2794 (7.2) |
| Type of IBD | |||
| CD | 21 547 (35.8) | — | — |
| UC | 38 589 (64.1) | — | — |
| Both diagnosis | 106 (0.2) | — | — |
| Medication exposure during March 1, 2020, to February 28, 2021b | |||
| 5-ASA | 16 625 (27.6) | 964 (4.5) | 15 635 (40.5) |
| Thiopurines | 3510 (5.8) | 1900 (8.8) | 1601 (4.1) |
| Methotrexate | 592 (1.0) | 293 (1.4) | 299 (0.8) |
| Systemic corticosteroids | 4748 (7.9) | 1627 (7.6) | 3106 (8.0) |
| Anti-TNF-α agents | 5299 (8.8) | 3427 (15.9) | 1859 (4.8) |
| Anti-interleukin therapeutic agents | 57 (0.1) | 19 (0.1) | 38 (0.1) |
| Selective immunosuppressive agents | 420 (0.7) | 328 (1.5) | 90 (0.2) |
| Ciclosporin/tacrolimus | 38 (0.1) | 11 (0.1) | 26 (0.1) |
Values are median (interquartile range) or n (%).
Abbreviations: 5-ASA, 5-aminosalicylic acid; CD, Crohn’s disease; IBD, inflammatory bowel disease; TNF-α, tumor necrosis factor α; UC, ulcerative colitis.
A total of 106 were registered with diagnoses of both UC and CD.
Time-varying exposures. Patients can have used medication in more than 1 of these categories in the exposure window.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
